Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | P2RY14 | Q15391 | 12/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24131122 | 0.88 | RIPK1 (0.49) | P2RY14RIPK1CYP11B1CYP11B2 | |
| SCHEMBL23336751 | 0.87 | L3MBTL1 (0.46) | L3MBTL1SRD5A2RIPK1CYP11B1CYP11B2 | |
| SCHEMBL24208611 | 0.83 | P2RY14 (0.47) | SRD5A2P2RY14 | |
| SCHEMBL3380852 | 0.83 | MAPT (0.46) | L3MBTL1SMN1; SMN2 | |
| SCHEMBL26202242 | 0.80 | P2RY14 (0.42) | SRD5A2P2RY14PPP1CASMN1; SMN2 | |
| SCHEMBL2360731 | 0.78 | L3MBTL1 (0.39) | L3MBTL1SRD5A2CYP11B1CYP11B2SMN1; SMN2 | |
| SCHEMBL3576265 | 0.75 | HCAR2 (0.42) | P2RY14 | |
| SCHEMBL8508062 | 0.75 | HCAR2 (0.39) | — | |
| SCHEMBL24131123 | 0.74 | ALDH1A1 (0.49) | RIPK1SMN1; SMN2 | |
| SCHEMBL3094695 | 0.74 | P2RY14 (0.55) | P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292340-A1 | CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2021-09-23 | — | — | US | disclosed |
| EP-3816163-A1 | CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2021-05-05 | — | — | EP | disclosed |
| CN-102282142-A | Substituted aryl compounds and their use | — | 2011-12-14 | — | — | CN | disclosed |
| US-20110301122-A1 | HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-08 | — | — | US | disclosed |
| US-20110301122-A1 | HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-08 | — | — | US | disclosed |
| US-20110301122-A1 | HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-08 | — | — | US | disclosed |
| EP-2356112-A1 | HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010054764-A1 | HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010054764-A1 | HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301122-A1 | HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS | HIF1AN, HIF1A, VHL | L3MBTL1 3733/4885SRD5A2 1070/4885P2RY14 3897/4885 |
| US-20210292340-A1 | CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | LITAF, RIPK1, RIPK2 | L3MBTL1 2786/4885SRD5A2 4396/4885P2RY14 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.